thoracic diseases
Conditions
Interventions
GroupR1:0.25% Ropivacaine 30ml+ dexamethasone 0.15mg/kg thoracic paravertebral nerve block
GroupR2:0.375% Ropivacaine 30ml+ dexamethasone 0.15mg/kg thoracic paravertebral nerve block
GroupR3:0.5% Ropivacaine 30ml+ dexamethasone 0.15mg/kg thoracic paravertebral nerve block
Sponsors
Chengdu Shangjin Nanfu Hospital-West China Shangjin Branch Department of Anesthesiology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: a) Patients undergoing elective thoracoscopic surgery under general anesthesia; b) Obtain the informed consent of the patient or the patient's family to receive regional nerve block and postoperative controlled intravenous analgesia; c)ASA grade I-II; d) Ages 18 to 65. e)BMI: 18-30 kg/m2
Exclusion criteria
Exclusion criteria: a) Abnormal spinal or paravertebral anatomy; b) Skin infection at the puncture site; c) Allergic to local anesthetics; d) Abnormal coagulation function; e) History of acute chronic pain or long-term use of sedative and analgesic drugs; f) severe hepatic and renal insufficiency; Severe respiratory and circulatory diseases; g) neurological or mental disorders; h) Pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS scores at different time points after surgery;Time of first compression of patient's analgesic pump;Morphine consumption in 48h after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Opioid-related adverse reactions;Incidence of local anesthetic poisoning after block;Pittsburgh Sleep Quality Index score; | — |
Countries
China
Contacts
Public ContactRurong Wang
Anesthesiology Department, 5th Floor, Chengdu Shangjin Nanfu Hospital, Chengdu High-Tech West District, Chengdu, Sichuan, China
Outcome results
None listed